Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6134030 | Journal of Virological Methods | 2013 | 6 Pages |
Abstract
HSV-1-based vectors have been widely used to achieve targeted delivery of genes into the nervous system. In the current study, we aim to use shRNA-containing HSV-1-based gene delivery system for the therapy of HSV-2 infection. Guinea pigs were infected intravaginally with HSV-2 and scored daily for 100 days for the severity of vaginal disease. HSV-2 shRNA-containing HSV-1 was applied intravaginally daily between 8 and 14 days after HSV-2 challenge. Delivery of HSV-2 shRNA-containing HSV-1 had no effect on the onset of disease and acute virus shedding in animals, but resulted in a significant reduction in both the cumulative recurrent lesion days and the number of days with recurrent disease. Around half of the animals in the HSV-2 shRNA group did not develop recurrent disease 100 days post HSV-2 infection. In conclusion, HSV-2 shRNA-containing HSV-1 particles are effective in reducing the recurrence of genital herpes caused by HSV-2.
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Zhihong Liu, Yang Xiang, Zhun Wei, Bo Yu, Yong Shao, Jie Zhang, Hong Yang, Manmei Li, Ming Guan, Jun Wan, Wei Zhang,